Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Next Big Thing In Drug Development May Be The Ubiquitin Pathway

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Velcade, Millennium’s successful first-in-class cancer therapy, is held up as a poster drug for manipulating the ubiquitin system to attack disease. Yet it taps only the most rudimentary process of an elegant and little understood cellular mechanism that some are betting will be the next big source of innovation in drug development.

You may also be interested in...



Third Rock Launches Nurix With Ambitions Of Next-Gen Velcade

The recently uncovered biotech a la Third Rock and The Column Group is focused on the ubiquitin protease pathway and its applications in oncology.

Celgene Returns To Forma’s Door, This Time With Option To Buy

The big biotech signed an expansive collaboration with the drug discovery company spanning multiple targets and numerous therapeutic areas. Celgene agreed to pay $225 million upfront and could eventually buy the company.

To Meet Demand, Forma Aims To Boost Discovery Supply

Forma Therapeutics has already convinced several big industry partners its discovery engine will yield oncology candidates in emerging areas of research. Now it wants to find academic groups to help feed its engine, all while the resurgent biotech IPO market might make its unusual structure superfluous.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel